HUMAN MONOCOLONAL ANTIBODIES FOR CNS REMYELINATION

Award Information
Agency:
Department of Health and Human Services
Branch
n/a
Amount:
$0.00
Award Year:
2002
Program:
STTR
Phase:
Phase I
Contract:
2R42NS040172-02
Agency Tracking Number:
NS040172
Solicitation Year:
n/a
Solicitation Topic Code:
n/a
Solicitation Number:
n/a
Small Business Information
ACORDA THERAPEUTICS, INC.
ACORDA THERAPEUTICS, INC., 15 SKYLINE DR, HAWTHORNE, NY, 10532
Hubzone Owned:
N
Minority Owned:
N
Woman Owned:
N
Duns:
n/a
Principal Investigator:
ERIC CHOJNICKI
(914) 347-4300
ECHOJNICKI@ACORDA.COM
Business Contact:
RON COHEN
(914) 347-4300
ROCHEN@ACORDA.COM
Research Institution:
MAYO FOUNDATION

MAYO FOUNDATION
ROCHESTER, MN, 55905

Domestic nonprofit research organization
Abstract
DESCRIPTION (provided by applicant): The primary goal of the current research will be to select the best recombinant form of one of two naturally occurring human igM antibodies demonstrated to stimulate remyelination to further develop for clinical testing in inflammatory demyelinating disease, such as MS. These antibodies, designated sHIgM22 and sHIgM46, were isolated by the Rodriquez laboratory at the Mayo Clinic by screening a bank of sera from patients with monoclonal gammopathy. The isolation, cloning and characterization of these antibodies were part of the specific aims of a Phase I STTR grant. The antibodies have been demonstrated to react with oligodendrocytes and to stimulate remyelination in the Theiler's Murine Encephalomyelitis Virus model in the SJL/J mouse. The specific aims of the current grant will be: Extend the characterization of each of these antibodies to the identification of the biologically relevant antigen and further elucidate the underlying mechanism by which the antibodies stimulate remyelination. Develop a robust scaleable manufacturing system that is suitable for producing commercial and clinical supplies of antibody. Extend the testing of the antibodies into other model systems of inflammatory CNS demyelinating disease and assess the toxicologic, pharmacokinetic and ADME properties of the antibodies.

* information listed above is at the time of submission.

Agency Micro-sites


SBA logo

Department of Agriculture logo

Department of Commerce logo

Department of Defense logo

Department of Education logo

Department of Energy logo

Department of Health and Human Services logo

Department of Homeland Security logo

Department of Transportation logo

Enviromental Protection Agency logo

National Aeronautics and Space Administration logo

National Science Foundation logo
US Flag An Official Website of the United States Government